Costarting sitagliptin with metformin is associated with a lower likelihood of disease progression in newly treated people with type 2 diabetes: a cohort study.

Campbell, S A

Costarting sitagliptin with metformin is associated with a lower likelihood of disease progression in newly treated people with type 2 diabetes: a cohort study. [electronic resource] - Diabetic medicine : a journal of the British Diabetic Association 10 2020 - 1715-1722 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1464-5491

10.1111/dme.14154 doi


Adult
Alberta
Cohort Studies
Diabetes Mellitus, Type 2--drug therapy
Disease Progression
Drug Therapy, Combination
Female
Glycated Hemoglobin--metabolism
Humans
Hypoglycemic Agents--therapeutic use
Logistic Models
Male
Metformin--therapeutic use
Middle Aged
Retrospective Studies
Sitagliptin Phosphate--therapeutic use